文献速递皮肤肿瘤

磷酸二酯酶5抑制剂与黑色素瘤风险:一项Meta分析

Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis.
PubMed 文献 · J Am Acad Dermatol · 2017-07-18

该Meta分析纳入5项观察性研究,评估PDE5抑制剂使用与皮肤癌风险的关联。结果显示PDE5抑制剂使用与黑色素瘤风险轻度但显著增加相关(OR 1.12,95%CI 1.03-1.21),与基底细胞癌风险也轻度增加相关(OR 1.14,95%CI 1.09-1.19),但与鳞状细胞癌无显著关联。

要点

  • PDE5抑制剂使用与黑色素瘤风险轻度增加相关(OR 1.12,95%CI 1.03-1.21)。
  • PDE5抑制剂使用与基底细胞癌风险轻度增加相关(OR 1.14,95%CI 1.09-1.19)。
  • PDE5抑制剂使用与鳞状细胞癌风险无显著关联。

核心结论

  • PDE5抑制剂使用可能与黑色素瘤和基底细胞癌风险轻度增加相关,但与鳞状细胞癌无关。
  • 需进一步大型前瞻性研究充分调整混杂因素后确认。

研究设计与样本

  • 系统检索PubMed、Embase、Cochrane对照试验中心注册库、Web of Science和ClinicalTrials.gov,截至2016年7月13日。
  • 纳入5项观察性研究,采用随机效应Meta分析计算调整比值比(OR)及95%置信区间(CI)。

主要发现

  • 与未使用PDE5抑制剂相比,使用PDE5抑制剂与黑色素瘤风险增加相关(OR 1.12;95%CI 1.03-1.21)。
  • 与未使用PDE5抑制剂相比,使用PDE5抑制剂与基底细胞癌风险增加相关(OR 1.14;95%CI 1.09-1.19)。
  • PDE5抑制剂使用与鳞状细胞癌风险无显著关联。
  • 预设因素(PDE5抑制剂剂量、研究设计、研究地区)对黑色素瘤风险结果均无显著影响(P > .05)。
  • 敏感性分析证实结果稳定性。

临床怎么用

  • 对使用PDE5抑制剂的患者,尤其是高风险人群,应关注皮肤癌筛查和监测。
  • 临床决策时需权衡PDE5抑制剂的获益与潜在的皮肤癌风险。

局限性

  • 仅纳入观察性研究,存在异质性且对潜在混杂因素的控制不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The association between phosphodiesterase type 5 (PDE5) inhibitors and melanoma risk is controversial. OBJECTIVE: We quantify the association between use of PDE5 inhibitors and melanoma. METHODS: We systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials.gov for studies that were conducted up to July 13, 2016, and evaluated the association between PDE5 inhibitors and skin cancer. Random effects meta-analyses were used to calculate the adjusted odds ratio (OR) with the 95% confidence interval (CI). RESULTS: Five observational studies were included. Compared with PDE5 inhibitor nonuse, PDE5 inhibitor use was slightly but significantly associated with an increased risk for development of melanoma (OR, 1.12; 95% CI, 1.03-1.21) and basal cell carcinoma (OR, 1.14; 95% CI, 1.09-1.19) but not squamous cell carcinoma. For melanoma risk, none of the prespecified factors (dose of PDE5 inhibitor, study design, and study region) significantly affected the results (P > .05). Our sensitivity analysis confirmed the stability of the results. LIMITATIONS: We included only observational studies, which had some heterogeneities and inconsistent controlling for potential confounders. CONCLUSIONS: Use of PDE5 inhibitors may be associated with a slightly increased risk for development of melanoma and basal cell carcinoma but not squamous cell carcinoma. However, further large well-conducted prospective studies with adequate adjustment for potential confounders are required for confirmation.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Tang H, Wu W, Fu S, et al. Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis. J Am Acad Dermatol. 2017. PMID: 28728871. doi:10.1016/j.jaad.2017.04.1129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。